NICE Grants Routine Access to Treatment for a Rare Metabolic Disorder - Medscape

Elosulfase alfa has been recommended for routine use within the NHS for the treatment of mucopolysaccharidosis type 4A.

In a draft guidance published yesterday, The National Institute for Health and Care Excellence (NICE) has recommended elosulfase alfa (Vimizin; BioMarin) for routine use within the NHS for the treatm… [+3175 chars]

full article...